Dr. Beatrix Metzner studied chemistry at the University of Regensburg and Freiburg, where she was specialized in biochemistry. Furthermore, she was a PhD student at the Department of Experimental Dermatology at the University of Freiburg and a Post -Doctoral research Fellow at the Memorial Sloan-Kettering Cancer Center in New York. From 2000, she worked at MediGene AG as Senior Scientist and later as Senior CMC Project Manager. In 2005, she started at Merck KGaA as CMC Project Manager. In 2007, she moved to Global Regulatory Oncology, where she has been workeding as Director of Global Regulatory Oncology, responsible for global regulatory strategy of biological products, until November 2013 responsible for global regulatory strategy of biological products. Currently, she acts as Director of CMC Strategy and Tech RA, responsible for CMC regulatory strategy of biosimilars at Boehringer Ingelheim.